自1976年成立以來，腫瘤免疫學(xué)、免疫治療(CII)在腫瘤免疫學(xué)領(lǐng)域取得了重大進(jìn)展。該雜志是一個論壇的新概念和進(jìn)展的基礎(chǔ)，翻譯，臨床癌癥免疫學(xué)和免疫治療。CII熱衷于發(fā)表廣泛的觀點(diǎn)和評論，擴(kuò)展或挑戰(zhàn)現(xiàn)有范式的結(jié)果，以及未能復(fù)制支持當(dāng)前范式的實(shí)驗的負(fù)面研究，以及在不同環(huán)境中成功復(fù)制他人結(jié)果的論文。除了發(fā)表原創(chuàng)研究論文和評論，CII還提供以下獨(dú)特的出版格式:·“聚焦研究綜述”，與會議報告一起發(fā)表，為每位演講者提供了機(jī)會來擴(kuò)展他們在會議上提出的想法和概念。·“書面研討會”，是一系列圍繞某一特定問題并針對該領(lǐng)域有爭議但具有戰(zhàn)略意義的主題的補(bǔ)充論文組成的虛擬研討會，通常由4-8篇論文和召集人的附帶評論組成。CII隸屬于癌癥免疫治療協(xié)會(CIMT)、加拿大癌癥免疫治療協(xié)會(CCIC)、日本癌癥免疫協(xié)會(JACI)、意大利生物腫瘤免疫治療網(wǎng)絡(luò)(NIBIT)、免疫腫瘤免疫治療和免疫監(jiān)測協(xié)會(CITIM)。

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:·“Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.·“Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), Sociedad Espa?ola de Immunologia-Grupo Espa?ol de ImmunoTerapia (SEI-GEIT), and Cancer Immunotherapy & Immunomonitoring (CITIM).